NASH a Big Opportunity For Gilead Sciences, Inc. (GILD)

After being a dominant player in the hepatitis C market with its drug Sovaldi, Gilead Sciences, Inc. (NASDAQ:GILD) is now eyeing to monetize from the next global epidemic, NASH, or nonalcoholic steatohepatitis. NASH is a modern day progressive liver-disease, stemming from obesity with no medication available so far. The disease is a bonanza to pharmaceutical companies like Gilead Sciences, Inc. (NASDAQ:GILD), as it is estimated that treatment costs for NASH could soar by as much as $40 billion over the next decade. A CNBC report throws light on how the disease could translate into big money to the pharmaceuticals along with the inputs from Deutsche Bank’s analyst, Alethia Young.

Gilead Sciences, Inc. (NASDAQ:GILD)

As drugmakers see the NASH affected cases to grow significantly in the upcoming years, Young cited: “At least, probably six million or six and a half million people with advanced NASH, meaning they have scarring or hardening of their liver. Conservatively, here in the U.S., then in Europe and the big five nations, it’s about the same. So, it’s about 12-13 million people.”

Those numbers are only an estimate of the people at advanced levels, therefore, if cases of preliminary or early stages are taken in account, then the patients are 30 million alone in the U.S. Thus, the market could be between $35 to $40 billion by 2020-2025.

Ahead of the potential market, three of the companies, Gilead Sciences, Inc. (NASDAQ:GILD), Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and France-based Genfit are in the race to develop the first Nash drug. The results of the ongoing studies in this direction will begin to unfold by the end of the year. But Young estimates that there is a need to wait for another couple of years in order to get satisfactory data about the safety and efficacy of the drugs as she sees the drugs hit the shelves only towards the year 2020. As of now, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) is the only company to provide positive data from its drug OCA (Obeticholic acid), after which its stocks have tripled in value. Analysts say that if companies add further positive results than their shares could double, but any negative data could mean a straight cut to half.

Disclosure: none

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!